NCT03151720View on ClinicalTrials.gov

A Study to Assess the Relative Bioavailability of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared to Clarityne Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

July 8, 2017

Study Completion Date

July 8, 2017

Conditions
Healthy
Interventions
DRUG

loratadine (Xisimin [Test Treatment])

Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.

DRUG

loratadine (Clarityne [Reference Treatment])

Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.

Trial Locations (1)

11490

Tri-Service Genaral Hospital, Taipei

All Listed Sponsors
lead

Xian-Janssen Pharmaceutical Ltd.

INDUSTRY

NCT03151720 - A Study to Assess the Relative Bioavailability of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared to Clarityne Tablets | Biotech Hunter | Biotech Hunter